Furthermore, a recent meta-analysis showed that GLP-1 receptor agonists significantly reduce circulating levels of inflammatory markers such as CRP and IL-6 in T2DM patients, reinforcing their anti-inflammatory and anti-atherosclerotic potential in clinical practice [78]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.